We are live on ! Find out more
NGM

NGM Biopharmaceuticals, Inc. Common Stock
NGM

Delisted

NGM was delisted on the 4th of April, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in NGM Biopharmaceuticals, Inc. Common Stock in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 75 → 0 (-75)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $55.1M → $0 (-$55.1M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 74

Holders
–
Holders Change
-75
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
74
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CG
Column Group
California
-$28.8M
2
BlackRock
BlackRock
New York
-$4.78M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$3.7M
4
SG
StepStone Group
California
-$2.5M
5
EC
Euclidean Capital
New York
-$1.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Column Group
California
– -$28.8M -18,136,735 Closed
BlackRock
2
BlackRock
New York
– -$4.78M -3,004,210 Closed
Vanguard Group
3
Vanguard Group
Pennsylvania
– -$3.7M -2,324,392 Closed
SG
4
StepStone Group
California
– -$2.5M -1,573,357 Closed
EC
5
Euclidean Capital
New York
– -$1.58M -992,168 Closed
Geode Capital Management
6
Geode Capital Management
Massachusetts
– -$1.56M -983,836 Closed
TC
7
Trium Capital
United Kingdom
– -$1.55M -977,965 Closed
State Street
8
State Street
Massachusetts
– -$1.31M -823,111 Closed
ACM
9
ADAR1 Capital Management
Texas
– -$1.3M -816,581 Closed
Renaissance Technologies
10
Renaissance Technologies
New York
– -$972K -611,300 Closed
Two Sigma Advisers
11
Two Sigma Advisers
New York
– -$804K -505,900 Closed
Northern Trust
12
Northern Trust
Illinois
– -$593K -372,733 Closed
Balyasny Asset Management
13
Balyasny Asset Management
Illinois
– -$573K -360,599 Closed
Citadel Advisors
14
Citadel Advisors
Florida
– -$544K -342,195 Closed
Charles Schwab
15
Charles Schwab
California
– -$453K -284,649 Closed
Goldman Sachs
16
Goldman Sachs
New York
– -$333K -209,298 Closed
ETC
17
Exchange Traded Concepts
Oklahoma
– -$296K -186,232 Closed
N
18
Natixis
France
– -$288K -181,366 Closed
BNP Paribas Financial Markets
19
BNP Paribas Financial Markets
France
– -$273K -171,397 Closed
Morgan Stanley
20
Morgan Stanley
New York
– -$247K -155,462 Closed
Dimensional Fund Advisors
21
Dimensional Fund Advisors
Texas
– -$246K -154,456 Closed
Bank of New York Mellon
22
Bank of New York Mellon
New York
– -$212K -133,225 Closed
Citigroup
23
Citigroup
New York
– -$171K -107,481 Closed
Connor, Clark & Lunn Investment Management (CC&L)
24
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$156K -98,037 Closed
N
25
Nuveen
North Carolina
– -$150K -94,178 Closed
1
2 3

NGM Hedge Fund Activity: Q2 2024 in Review

0 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q2 2024, worth a combined $0 — down 100% from $55.1M a quarter earlier.

Sellers outnumbered buyers: 74 funds closed out of NGM and 0 opened new positions — a net loss of 74 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Column Group, exiting entirely with an estimated $28.8M sold.

  • 0 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q2 2024, down from 75 in Q1 2024.
  • Funds reported $0 of NGM Biopharmaceuticals, Inc. Common Stock stock for Q2 2024, down 100% quarter-over-quarter.
  • 0 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q2 2024 and 74 closed out, a net change of -74 holders.
  • The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q2 2024 was Column Group, an estimated $28.8M sold.

Based on aggregated 13F filings for Q2 2024.